

2022

- Voss M, Pinkert S, Kespohl M, Gimber N, Klingel K, Schmoranzer J, Laue M, Gaida M, Kloetzel OM, **Beling A**. A Conserved Cysteine Residue in Coxsackievirus B3. Protein 3A with Implication for Elevated Virulence. **Viruses** 2022, 14, 769. <https://doi.org/10.3390/v14040769> (IF 5.0)
- Voss M, Kleinau G, Gimber N, Janek K, Bredow C, Thery F, Impens F, Schmoranzer J, Scheerer P, Kloetzel PM, **Beling A**. A cytosolic disulfide bridge-supported dimerization is crucial for stability and cellular distribution of Coxsackievirus B3 protein 3A. **FEBS J.** 2022 Jan 23. doi: 10.1111/febs.16368. (IF 5.5)

2021

- Voss M, Braun V, Bredow C, Kloetzel PM, **Beling A**. Coxsackievirus B3 Exploits the Ubiquitin-Proteasome System to Facilitate Viral Replication. **Viruses**. 2021;13(7):1360. doi: 10.3390/v13071360 (IF 5.0)
- Thery F, Martina L, Asselman C, Vessely M, Zhang Y, Repo H, Sedeyn K, Moschonas GD, Bredow C, Wen Teo Q, Zhang J, Leandro K, Eggermont D, De Sutter D, Boucher K, Hochepped T, Festjens N, Callewaert N, Saelens X, Dermaut B, Knobloch KP, **Beling A**, Sanyal S, Radoshevich L, Eyckerman S, Impens F. Ring Finger Protein 213 Assembles into a Sensor for ISGylated Proteins with Antimicrobial Activity, **Nature Communications** 2021;12(1):5772. doi: 10.1038/s41467-021-26061-w. (IF 14.9)
- Munnur D, Teo Q, Eggermont D, Lee HHY, Thery F, Ho J, van Leur SW, Ng WWS, Siu LYL, **Beling A**, Ploegh H, Pinto-Fernandez A, Damianou A, Kessler B, Impens F, Pun Mok CK and Sanyal S. Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection, **Nature Immunology**, 2021;22(11):1416-1427. doi: 10.1038/s41590-021-01035-8. (IF 25.6)
- Pinkert S, Kespohl M, Kelm N, Kaya Z, Heuser A, Klingel K, **Beling A**. Exploration of Analgesia with Tramadol in the Coxsackievirus B3 Myocarditis Mouse Model. **Viruses** 2021; 13(7):1222. doi.org/10.3390/v13071222 (IF 5.1)
- Goetzke CG, Althof N, Neumaier HL, Heuser A, Kaya Z, Kespohl M, Klingel K, **Beling A**. Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection. **Basic Research in Cardiology** 2021 116, 7 (2021). doi.org/10.1007/s00395-021-00848-w (IF 15.5)
- Böhnke J, Pinkert S, Schmidt M, Binder H, Bilz NC, Jung M, Reibetanz U, **Beling A**, Rujescu D, Claus C. Coxsackievirus B3 Infection of Human iPSC Lines and Derived Primary Germ-Layer Cells Regarding Receptor Expression. **International Journal of Molecular Sciences** 2021, 22, 1220. doi.org/10.3390/ijms22031220 (IF 5.9)
- Hazini, A., Dieringer, B., Pryshliak, M., Knoch, K.P., Heimann, L., Tolksdorf, B., Pappritz, K., El-Shafeey, M., Solimena, M., **Beling, A.**, Kurreck, J., Klingel, K., Fechner, H. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. **Human Gene Therapy** 2021;32(3-4):216-30. doi: [10.1089/hum.2020.228](https://doi.org/10.1089/hum.2020.228) (IF 5.7)

2020

- *Pinkert S, Kopp A, Brückner V, Fechner H, Beling A. Single point mutations within the Coxsackie B virus receptor-binding site promote resistance against soluble virus receptor traps. **Journal of Virology** 2020, 94(19):e00952-20. doi: 10.1128/JVI.00952-20 (IF 5.1)*
- *Neumaier HL, Harel S, Klingel K, Kaya Z, Heuser A, Kespohl M and **Beling A**. ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of*

NMRI Mice and Promotes Virus-Mediated Tissue Damage. **Cells** 2020, 9(5), 1093; doi.org/10.3390/cells9051093 (IF 6.6)

- Bockstahler M, Fischer A, Goetzke CC, Neumaier HL, Sauter M, Kespohl M, Müller AM, Meckes C, Salbach C, Schenk M, Heuser A, Landmesser U, Weiner J, Meder B, Lehmann L, Kratzer A, Klingel K, Katus HA, Kaya Z, **Beling A**. Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation. **Circulation** 2020; 141:1885–1902 doi: 10.1161/CIRCULATIONAHA.119.043171. (IF 29.6)
- Kespohl M, Bredow C, Klingel K, Voß M, Paeschke A, Zickler M, Poller W, Kaya Z, Eckstein J, Fechner H, Spranger J, Föhling M, Wirth EK, Radoshevich L, Thery F, Impens F, Berndt N, Knobloch KP, **Beling A**. Protein modification with ISG15 blocks Coxsackievirus pathology by antiviral and metabolic reprogramming. **Science Advances** (Sci Adv.) 2020; 6(11):eaay1109. doi: 10.1126/sciadv.aay1109 (IF 14.1)

2019

- Zhang Y, Thery F, Wu NC, Luhmann EK, Dussurget O, Foecke M, Bredow C, Jiménez-Fernández D, Leandro K, **Beling A**, Knobloch KP, Impens F, Cossart P, Radoshevich L. *The in vivo ISGylome links ISG15 to metabolic pathways and autophagy upon Listeria monocytogenes infection.* **Nat Commun.** 2019;10(1):5383. (IF 11.9)
- Pinkert S, Pryshliak M, Pappritz K, Knoch K, Hazini A, Dieringer B, Schaar K, Dong F, Hinze L, Lin J, Lassner D, Klopffleisch R, Solimena M, Tschöpe C, Kaya Z, **Beling A**, Kurreck J, van Linthout S, Klingel K, Fechner H. *Development of a New Mouse Model for Coxsackievirus-Induced Myocarditis by Attenuating Coxsackievirus B3 Virulence in the Pancreas.* **Cardiovasc Res.** 2019. pii: cvz259. doi: 10.1093/cvr/cvz259 (IF 8.2)
- Pinkert S, Dieringer B, Klopffleisch R, Savvatis K, Van Linthout S, Pryshliak M, Tschöpe C, Klingel K, Kurreck J, **Beling A***, Fechner H*. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. *Circ Heart Fail.* 2019;12(11):e005250. doi: 10.1161/CIRCHEARTFAILURE.119.005250. (IF 6.5), * equal contribution

2018

- **Beling, A.**, and Kespohl, M. (2018). Proteasomal Protein Degradation: Adaptation of Cellular Proteolysis With Impact on Virus—and Cytokine-Mediated Damage of Heart Tissue During Myocarditis. **Frontiers in immunology** 9. (IF 4.7)
- Meyer, I.S.*, Goetzke, C.C.*, Kespohl, M., Sauter, M., Heuser, A., Eckstein, V., Vornlocher, H.-P., Anderson, D.G., Haas, J., Meder, B., Katus HA, Klingel K, **Beling A***, Leuschner F*. (2018). Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis. **Frontiers in immunology** 9. (IF 4.7)
- Napolitano A, van der Veen AG, Bunyan M, Borg A, Frith D, Howell S, Kjaer S, **Beling A**, Snijders AP, Knobloch KP, Frickel EM. *Cysteine-Reactive Free ISG15 Generates IL-1 β -Producing CD8 α^+ Dendritic Cells at the Site of Infection.* **J Immunol.** 2018 Jun 11. pii: ji1701322. doi: 10.4049/jimmunol.1701322. (IF 4.7)
- Althof N, Goetzke CC, Kespohl M, Voss K, Heuser A, Pinkert S, Kaya Z, Klingel K, **Beling A**. *The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis.* **EMBO Mol Med.** 2018;10(2):200-218. (IF 10.6)
- Loebel M, Holzhauser L, Hartwig JA, Shukla PC, Savvatis K, Jenke A, Gast M, Escher F, Becker SC, Bauer S, Stroux A, **Beling A**, Kespohl M, Pinkert S, Fechner H, Kuehl U, Lassner D, Poller W, Schultheiss HP, Zeller T, Blankenberg S, Papageorgiou AP, Heymans S, Landmesser U, Scheibenbogen C, Skurk C. *The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis.* **Eur Heart J.** 2018; 39(10):876-887. (IF 24.9)

2017

- Respondek D, Voss M, Kühlewindt I, Klingel K, Krüger E, **Beling A**. *PA28 modulates antigen processing and viral replication during coxsackievirus B3 infection*. **PLoS One**. 2017; 9;12(3):e0173259. (IF 2.8)

2016

- Spur EM, Althof N, Respondek D, Klingel K, Heuser A, Overkleeft HS, **Voigt A**. *Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes*. **Toxicology**. 2016; 353-354:34-47. (IF 3.6)
- Gast M, Schroen B, **Voigt A**, Haas J, Kuehl U, Lassner D, Skurk C, Escher F, Wang X, Kratzer A, Michalik K, Papageorgiou A, Peters T, Loebel M, Wilk S, Althof N, Prasanth KV, Katus H, Meder B, Nakagawa S, Scheibenbogen C, Schultheiss HP, Landmesser U, Dimmeler S, Heymans S, Poller W. *Long noncoding RNA MALAT1-derived mascRNA is involved in cardiovascular innate immunity*. **Journal of Molecular and Cellular Biology** 2016, 8(2):178-181. (IF 6.8)
- Paeschke A*, Possehl A*, Klingel K, Voss M, Voss K, Kesphol M, Sauter M, Overkleeft HS, Althof N, Garlanda C, **Voigt A**. The availability of the cardio-protective pattern recognition molecule Pentraxin3 is controlled by the immunoproteasome. **European Journal of Immunology** 2016; 46(3):619-633. (IF 4.6)